Press Releases April 20, 2026 04:05 PM

Ceribell to Report First Quarter 2026 Financial Results on May 11, 2026

Ceribell Announces Q1 2026 Earnings Release and Conference Call for May 11, 2026

By Derek Hwang
Share
Twitter Reddit Facebook LinkedIn
CBLL

CeriBell, Inc., a medical technology company specializing in neurological diagnostics, announced that it will release its first quarter 2026 financial results on May 11, 2026, after the market closes. The company will hold a conference call to discuss results and provide investors with updates on its innovative EEG diagnostic platform.

Ceribell to Report First Quarter 2026 Financial Results on May 11, 2026
CBLL
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Ceribell will report Q1 2026 financial results on May 11 after market close with a conference call for investors.
  • The company develops the Ceribell System, an AI-powered point-of-care EEG platform for rapid diagnosis and monitoring of neurological conditions in acute-care settings.
  • Ceribell's system is FDA-cleared for seizure and delirium detection in ICUs and emergency rooms, positioning the company in the medical technology and healthcare sectors.

SUNNYVALE, Calif., April 20, 2026 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today announced that it will release financial results for the first quarter of 2026 after the close of trading on Monday, May 11, 2026. Company management will host a conference call to discuss financial results beginning at 1:30 p.m. PT / 4:30 p.m. ET on May 11, 2026.

Investors interested in listening to the conference call may do so by dialing (800) 715-9871 for domestic callers or (646) 307-1963 for international callers and providing access code 1880547. A live and archived webcast of the event will be available in the "Investor Relations" section of the Ceribell website at https://investors.ceribell.com/.

About CeriBell, Inc.
Ceribell is a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. Ceribell has developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute-care setting. By combining proprietary, highly portable, and rapidly deployable hardware with sophisticated artificial intelligence (“AI”)-powered algorithms, the Ceribell System enables rapid diagnosis and continuous monitoring of patients with neurological conditions. The Ceribell System is FDA-cleared for use in detecting seizure and delirium in intensive care units and emergency rooms across the U.S. Ceribell is headquartered in Sunnyvale, California. For more information, please visit www.ceribell.com or follow the company on LinkedIn.

Investor Contact
Brian Johnston
Gilmartin Group
[email protected]

Media Contact
Brian Price
[email protected]  


Risks

  • Financial results could fall short of investor expectations, impacting share price within the healthcare technology sector.
  • Regulatory challenges or delays in FDA approvals for new products could impede growth and market expansion.
  • Market adoption and competition from other neurological diagnostic technologies may limit revenue growth potential.

More from Press Releases

Agios Showcases RISE UP Phase 3 Results at EHA 2026 Plenary Session Reinforcing Strong Anti-Hemolytic Profile of Mitapivat in Sickle Cell Disease Jun 13, 2026 Rhythm Pharmaceuticals Presents Positive Interim Six-month Data from Phase 2 Trial of Setmelanotide in Patients with Prader-Willi Syndrome (PWS) at ENDO 2026 Jun 13, 2026 Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema Jun 13, 2026 Arcadia Biosciences (RKDA) Announces Closing of $4 Million Private Placement Priced At-The-Market Under Nasdaq Rules Jun 12, 2026 Belite Bio Completes Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Tinlarebant for the Treatment of Stargardt Disease Type 1 Jun 12, 2026